Resistant Hypertension Clinical Trial
Official title:
Effectiveness and Safety of Superselective Adrenal Arterial Embolization (SAAE) for Resistant Hypertension: A Randomized, Parallel, Controlled Clinical Trial
Resistant hypertension (RH) is usually defined as blood pressure (BP) that remains above guideline-specified targets despite the use of three or more antihypertensive agents at optimal or maximally tolerated doses, with one of those agents preferably being a diuretic. It is not uncommon, being identified in 10 to 30% of hypertensive patients and it is known to be a risk factor for cardiovascular (CV) events, including stroke, myocardial infarction (MI), heart failure (HF), and CV mortality, as well as adverse renal events,including chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The activation of the renin-angiotensin-aldosterone system (RAAS) and sympatho-adrenomedullary system can play a pathogenic role in triggering and sustaining RH. SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines. Therefore, SAAE is a minimally invasive procedure that might be used as an alternative strategy to antihypertensive drugs or reduce the intensity of antihypertensive drugs.
Status | Not yet recruiting |
Enrollment | 144 |
Est. completion date | March 31, 2025 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Male or female, aged between 18-65 years old. - Patients with resist hypertension (office systolic blood pressure =140 mmHg, and/or office diastolic blood pressure =90 mmHg, and/or 24-h average systolic blood pressure =130 mmHg) with rational lifestyle change and triple antihypertensive drugs (irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d) for at least 4 weeks. - Informed consent signed and agreed to participate in this trial. Exclusion Criteria: - Secondary hypertension - Adrenergic insufficiency. - adrenocortical insufficiency - Renal failure eGFR<60 mL/min/1.73 m2 - Heart failure with NYHA grade ?-? grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events. - Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts. - Liver dysfunction or the following history of liver disease: AST or ALT 3 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history. - Fertile woman without contraceptives. - Coagulation dysfunction. - Pregnant women or lactating women. - Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial. - Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug. - Allergy or any contraindications for the study drugs, contrast agents and alcohol. - History of depression, schizophrenia or vascular dementia. - Refused to sign informed consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Chengdu Medical College |
Bourque G, Hiremath S. Rethinking Resistant Hypertension. J Clin Med. 2022 Mar 7;11(5). pii: 1455. doi: 10.3390/jcm11051455. Review. — View Citation
Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, Xu B, Gao R, Jiang X. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. Catheter Cardiovasc Interv. 2021 May 1;97 Suppl 2:976-981. — View Citation
Giurazza F, Corvino F, Silvestre M, Cangiano G, Cavaglià E, Amodio F, De Magistris G, Frauenfelder G, Niola R. Adrenal glands hemorrhages: embolization in acute setting. Gland Surg. 2019 Apr;8(2):115-122. doi: 10.21037/gs.2018.10.06. — View Citation
Zhao Z, Liu X, Zhang H, Li Q, He H, Yan Z, Sun F, Li Y, Zhou X, Bu X, Wu H, Shen R, Zheng H, Yang G, Zhu Z; Chongqing Endocrine Hypertension Collaborative Team. Catheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controll — View Citation
Zhou Q, Liu X, Zhang H, Zhao Z, Li Q, He H, Zhu Z, Yan Z. Adrenal Artery Ablation for the Treatment of Hypercortisolism Based on Adrenal Venous Sampling: A Potential Therapeutic Strategy. Diabetes Metab Syndr Obes. 2020 Oct 6;13:3519-3525. doi: 10.2147/DM — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of 24-h average systolic blood pressure | Difference in the change of 24-h average systolic blood pressure between the intervention and control group | 6-month | |
Secondary | Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure | Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group | 6-month | |
Secondary | Change of the number of antihypertensive medications | Difference in the change of the number of antihypertensive medications between the intervention and control group | 6-month | |
Secondary | Change of home systolic and diastolic pressure | Difference in the change of home systolic and diastolic pressure between the intervention and control group | 6-month | |
Secondary | Change of office systolic and diastolic pressure | Difference in the change of office systolic and diastolic pressure between the intervention and control group | 6-month | |
Secondary | Change of blood electrolytes (K+, Na +) | Difference in the change of blood electrolytes (K+, Na + in mmol/L) between the intervention and control group | 6-month | |
Secondary | Change of plasma aldosterone | Difference in the change of plasma aldosterone (pg/mL) between the intervention and control group | 6-month | |
Secondary | Change of plasma cortisol | Difference in the change of plasma cortisol (nmol/L) between the intervention and control group | 6-month | |
Secondary | Change of plasma renin measured | Difference in the change of plasma renin (pg/ml) between the intervention and control group | 6-month | |
Secondary | Change of liver enzymes | Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group | 6-month | |
Secondary | Change of kidney function | Difference in the change of serum creatinine in umol/L between the intervention and control group | 6-month | |
Secondary | Change of fasting blood glucose | Difference in the change of fasting blood glucose in mmol/L between the intervention and control group | 6-month | |
Secondary | Change of lipids profiles | Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L between the intervention and control group | 6-month | |
Secondary | Change of 24-h urine microalbumin | Difference in the change of 24-h urine microalbumin (mg/L) between the intervention and control group | 6-month | |
Secondary | Change of 24-h 24-h urine creatinine | Difference in the change of 24-h urine creatinine (umol/L) between the intervention and control group | 6-month | |
Secondary | Change of echocardiography parameters (LVEF) | Difference in the change of cardiac parameters assessed by echocardiography LVEF (%) between the intervention and control group | 6-month | |
Secondary | Change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD) | Difference in the change of echocardiography parameters (IVSd?IVSs?LVPWd, LVPWs, LVEDD, in millimetre[mm]) between the intervention and control group | 6-month | |
Secondary | Change of carotid intima-media thickness | Difference in the change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound between the intervention and control group | 6-month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05545059 -
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
|
Phase 3 | |
Not yet recruiting |
NCT04388124 -
VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
|
Phase 2 | |
Withdrawn |
NCT01939392 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06228677 -
Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
|
||
Recruiting |
NCT04213963 -
Prospective Study on Primary Aldosteronism in Resistant Hypertension
|
||
Recruiting |
NCT05563077 -
Aerobic Exercise and Resistant Hypertension
|
N/A | |
Recruiting |
NCT03758196 -
Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH)
|
N/A | |
Active, not recruiting |
NCT03179800 -
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
|
N/A | |
Completed |
NCT04519658 -
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
|
Phase 2 | |
Not yet recruiting |
NCT05426707 -
Remote Ischemic Conditioning for the Treatment of Resistant Hypertension
|
N/A | |
Completed |
NCT04345198 -
Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension
|
N/A | |
Active, not recruiting |
NCT05562934 -
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
|
Phase 2 | |
Recruiting |
NCT06034743 -
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
|
Phase 3 | |
Withdrawn |
NCT02926495 -
Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.
|
N/A | |
Active, not recruiting |
NCT02670681 -
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
|
N/A | |
Completed |
NCT02572024 -
The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study)
|
N/A | |
Terminated |
NCT02295683 -
Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
|
||
Completed |
NCT02001350 -
Carotid Ultrasound Study
|
N/A | |
Recruiting |
NCT04331691 -
Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension
|
Phase 4 | |
Recruiting |
NCT04637152 -
Sacubitril/Valsartan in Resistant Hypertension
|
Phase 2 |